Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption in GBM Patients
InSightec
InSightec
National Institutes of Health Clinical Center (CC)
University of Calgary
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Ohio State University Comprehensive Cancer Center
Mayo Clinic
National Institutes of Health Clinical Center (CC)
Medical College of Wisconsin
Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Chiang Mai University
Maastricht Radiation Oncology
Virginia Commonwealth University
Peking University First Hospital
Thomas Jefferson University
St. Jude Children's Research Hospital
Maastricht Radiation Oncology
West China Hospital
West China Hospital
West China Hospital
West China Hospital
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Fondation Ophtalmologique Adolphe de Rothschild
Sunnybrook Health Sciences Centre
Universitätsklinikum Hamburg-Eppendorf
Centre Hospitalier Universitaire de Nīmes
Stanford University
Assistance Publique - HĂ´pitaux de Paris
Beijing Tiantan Hospital
Massachusetts General Hospital
Arbor Pharmaceuticals, Inc.
Varian, a Siemens Healthineers Company
Centre Jean Perrin
Hellenic Cooperative Oncology Group
Assistance Publique - HĂ´pitaux de Paris
Fondation Ophtalmologique Adolphe de Rothschild
Mayo Clinic
Corewell Health West
Huashan Hospital
Universitat Politècnica de València
Universitat Politècnica de València
Universitat Politècnica de València
Fondation Ophtalmologique Adolphe de Rothschild
Central Hospital, Nancy, France
Central Hospital, Nancy, France
Memorial Sloan Kettering Cancer Center
University of Arkansas
Children's Oncology Group